Keywords: az, hrpc, drug, yields, drop, death, risk
AZ's HRPC drug yields 45% drop in death risk
Article | 08 December 2008
AstraZeneca's ZD4054 could improve overall survival in men with metastatic hormone-resistant prostate cancer who were asymptomatic or mildly symptomatic for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
